A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction
AUTOR(ES)
Barkin, Robert L.
FONTE
Physicians Postgraduate Press
RESUMO
Background: Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is characterized by a unique receptor-specific pharmacologic profile and tolerable side-effect profile in comparison to other antidepressants. It has been reported to have a low incidence of agitation, anxiety, and insomnia, which may be due to blockade of 5-HT2 and 5-HT3 receptors. This unique multireceptor-mediated clinical pharmacologic profile may reduce the need for polypharmacy in selected patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=181080Documentos Relacionados
- Sexual compulsivity, anxiety, depression, and sexual risk behavior among treatment-seeking men in São Paulo, Brazil
- Anxiety, Depression, Stress and the Heart: When Measurement Matters
- Phantom pain, anxiety, depression, and their relation in consecutive patients with amputated limbs: case reports
- Assessment of anxiety, depression, loneliness and stigmatization in patients with tuberculosis
- The Effect of Dialectic Behavioral Counseling on Depression, Anxiety, and Postpartum Hematocrit Level